

<u>Laboratory Testing Algorithm</u> for Patients with Suspect 2019 Novel Coronavirus (COVID-19)

Document last updated: 3/2/2020

Patient must meet clinical features criteria AND epidemiological risk criteria for testing authorization.

Clinical Features	&	Epidemiologic Risk
Fever ¹ or signs/symptoms of lower respiratory illness (e.g. cough or shortness of breath)	AND	Any person, including healthcare workers ² , who has had close contact ³ with a laboratory-confirmed ⁴ COVID-19 patient within 14 days of symptom onset
Fever ¹ and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath) requiring hospitalization	AND	A history of travel from affected geographic areas ⁵ (see below) within 14 days of symptom onset
Fever ¹ with severe acute lower respiratory illness (e.g., pneumonia, ARDS) requiring hospitalization and without alternative explanatory diagnosis (e.g., influenza) ⁶	AND	No source of exposure has been identified

If patient meets **CLINICAL** <u>AND</u> **EPIDEMIOLOGICAL RISK** criteria as a person under investigation (PUI), place patient in contact and airborne isolation and call ISDH immediately for testing authorization at 317-233-7125, M-F 8:15 a.m. - 4:45 p.m. After hours, call 317-233-1325.

- 1 Fever may be subjective or confirmed.
- 2 For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19 without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially exposed healthcare personnel.
- 3 Close contact is defined as: a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time; close contact can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case OR b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on). If such contact occurs while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.
- 4 Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for patients in other countries.
- 5 Affected areas are defined as geographic regions where sustained community transmission has been identified. Relevant affected areas will be defined as a country with <u>at least a CDC Level 2 Travel Health Notice</u>.
- 6 Category includes single or clusters of patients with severe acute lower respiratory illness (e.g., pneumonia, ARDS) of unknown etiology in which COVID-19 is being considered.